Overexpression of the miR-143/145 and reduced expression of the let-7 and miR-126 for early lung cancer diagnosis
Journal of Applied Biomedicine · 17.03.2022 · 20 (1) · 1-6
DOI: 10.32725/jab.2022.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Biomedicine, erschienen am 17.03.2022. Verfasst von Lubomir Tulinsky und 3 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Ostrava, Department of Surgery, Ostrava, Czech Republic. Hauptthemen laut MEDLINE: Lung Neoplasms, MicroRNAs. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Hospital Ostrava, Department of Surgery, Ostrava, Czech Republic.
- Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Department of Thoracic Surgery, Martin, Slovak Republic.
- Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Biomedical Center Martin, Martin, Slovak Republic.
Zitieren
APA
Tulinsky, L., Dzian, A., Matakova, T., & Ihnat, P. (2022). Overexpression of the miR-143/145 and reduced expression of the let-7 and miR-126 for early lung cancer diagnosis. Journal of Applied Biomedicine, 20(1), 1-6. https://doi.org/10.32725/jab.2022.004
Vancouver
Tulinsky L, Dzian A, Matakova T, Ihnat P. Overexpression of the miR-143/145 and reduced expression of the let-7 and miR-126 for early lung cancer diagnosis. Journal of Applied Biomedicine. 2022;20(1):1-6. doi:10.32725/jab.2022.004
BibTeX
@article{Tulinsky2022,
author = {Tulinsky, Lubomir and Dzian, Anton and Matakova, Tatiana and Ihnat, Peter},
title = {Overexpression of the miR-143/145 and reduced expression of the let-7 and miR-126 for early lung cancer diagnosis},
journal = {Journal of Applied Biomedicine},
year = {2022},
volume = {20},
number = {1},
pages = {1--6},
doi = {10.32725/jab.2022.004}
}
EUVIMED